Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TC-3 is a proprietary reverse thermal biodegradable hydrogel developed by UroGen Pharma (formerly TheraCoat Ltd.). It is designed as a drug delivery system for intravesical administration, primarily in the urinary bladder. The hydrogel is characterized by its ability to remain in a liquid state at cold temperatures (5°C) and transition into a solid gel upon reaching body temperature. This property allows it to form a localized drug reservoir within the bladder, facilitating the sustained release and prolonged contact of co-administered active pharmaceutical ingredients, such as Mitomycin C (MMC) or Botulinum Toxin A (BTX), with the bladder urothelium. This extended exposure aims to enhance the therapeutic efficacy and duration of treatment for various urological conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TC-3.